Difference between revisions of "Triptorelin (Trelstar LA)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Endocrine therapy" to "Category:Endocrine therapeutic") |
m (→References) |
||
| Line 32: | Line 32: | ||
[[Category:FDA approved in 2000]] | [[Category:FDA approved in 2000]] | ||
| − | |||
Revision as of 15:24, 1 October 2019
General information
Class/mechanism: GnRH (gonadotropin-releasing hormone)/LHRH (luteinizing hormone releasing hormone) agonist; inhibits gonadotropin secretion, decreasing circulating levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone), and suppressing synthesis of ovarian and testicular steroids.[1][2]
Route: IM
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 6/15/2000: Initial FDA approval "in the palliative treatment of advanced prostate cancer."
Also known as
- Brand names: Decapeptyl, Diphereline, Gonapeptyl, Trelstar LA, Variopeptyl